tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Axsome Therapeutics (AXSM) and Treace Medical Concepts (TMCI)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intra-Cellular Therapies (Research Report).

Intra-Cellular Therapies (ITCI)

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Intra-Cellular Therapies, with a price target of $70.00. The company’s shares closed last Wednesday at $58.87.

According to 3.0% and a 47.8% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intra-Cellular Therapies with a $71.13 average price target, a 24.1% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $90.00 price target.

See today’s best-performing stocks on TipRanks >>

Axsome Therapeutics (AXSM)

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Axsome Therapeutics today and set a price target of $55.00. The company’s shares closed last Wednesday at $46.49, close to its 52-week high of $47.49.

According to -17.6% and a 31.0% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Foghorn Therapeutics, and Talaris Therapeutics.

Axsome Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $69.11.

Treace Medical Concepts (TMCI)

Morgan Stanley analyst Drew Ranieri maintained a Buy rating on Treace Medical Concepts today and set a price target of $23.00. The company’s shares closed last Wednesday at $19.40.

According to -5.5% and a 41.4% success rate. Ranieri covers the Healthcare sector, focusing on stocks such as Baxter International, Integra Lifesciences, and Intuitive Surgical.

Treace Medical Concepts has an analyst consensus of Strong Buy, with a price target consensus of $22.33, a 17.5% upside from current levels. In a report released yesterday, BTIG also reiterated a Buy rating on the stock with a $23.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ITCI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More